• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

10.18 +0.02 (+0.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 878,804
Open 10.29
Bid (Size) 10.20 (100)
Ask (Size) 10.30 (500)
Prev. Close 10.16
Today's Range 10.03 - 10.37
52wk Range 4.350 - 14.00
Shares Outstanding 28,919,810
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2026
From Candel Therapeutics
Via GlobeNewswire

Performance

52-Week Range 27.3% below 52-week high
10.18
4.3552W Low 14.0052W High
1 Week 11.6% below 1-week high
10.031W Low 11.521W High

Candel Therapeutics, Inc. - Common Stock (CADL) traded between $4.35 and $14.00 over the past 52 weeks and last traded at $10.18, 27.3% below its 52-week high. Over the past week it ranged between $10.03 and $11.52.

Past 12 Months
-9.0%
-22.9%
+1.5%
+102.8%
+87.1%
+88.2%
1W -$1.01
1M -$3.02
3M +$0.15
6M +$5.16
YTD +$4.74
1Y +$4.77

CADL was +88.2% over the past year, +102.8% over six months, +87.1% year to date, -9.0% in the last week.

12 Months vs Market
CADL
+88.2%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months CADL returned +88.2% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.71× 3-mo avg
Today 878,804 3-mo avg 1.2M
1W
983.9K
1M
1.2M
3M
1.2M
6M
1.7M
YTD
1.5M
1Y
1.3M

CADL most recently traded 878,804 shares against a 3-month average daily volume of 1.2M.

More News

Read More
News headline image
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate
October 01, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 30, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at September Investor Conferences
August 26, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up ↗
August 12, 2026
Via MarketBeat
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 03, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
June 30, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
June 25, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
June 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data ↗
May 20, 2026
Via MarketBeat
News headline image
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
May 15, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Upcoming Investor Conferences
May 13, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 04, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From Candel Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?
Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
What is the current price of Candel Therapeutics, Inc. - Common Stock?
The current price of Candel Therapeutics, Inc. - Common Stock is 10.18
When was Candel Therapeutics, Inc. - Common Stock last traded?
The last trade of Candel Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
The market capitalization of Candel Therapeutics, Inc. - Common Stock is 294.40M
How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
Candel Therapeutics, Inc. - Common Stock has 294M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap